OxyContin Makers Sued Over Marketing of Drug June 15, 2001
News Summary
The state of West Virginia is suing the makers of OxyContin for allegedly encouraging misuse of the painkiller, the Associated Press reported June 11.The lawsuit claims that Purdue Frederick Co., and its associated companies Purdue Pharma L.P., Purdue Pharma Inc., Abbott Laboratories Inc., and Abbott Laboratories used "highly coercive and inappropriate tactics" in convincing doctors and pharmacists to prescribe and fill prescriptions for the drug, "often when it was not called for."
The suit further states that the makers of the drug failed to warn doctors of the drug's potential for abuse. Nationwide, OxyContin has been linked to at least 120 overdose deaths.
The lawsuit connects the companies' practices to unnecessary prescription of the drug to West Virginia residents under the state's Medicaid program. According to the state, about $4.6 million of the state Medicaid program's pharmacy benefits were spent on OxyContin in 2000.
"We're concerned about the use and abuse of OxyContin, and if there are things the manufacturer is doing to increase that, then we need to put a stop to that," said Paul Nusbaum, head of the state's health-services agency.
The drug is generally prescribed to terminal cancer patients and chronic-pain sufferers. The active ingredient in OxyContin can give the same kind of euphoric feeling as heroin. While the drug is supposed to be time-released, abusers crush the pills and inhale or inject the powder to get high.
Purdue Pharma officials said they have not seen a copy of the lawsuit, but released a statement that said, "We will vigorously defend ourselves and fully expect to prevail. We want the many thousands of patients in West Virginia receiving pain relief from OxyContin tablets to rest assured that nothing in this case or any other case will cause us to abandon them or deter us from making sure that our drug is available to them."
The lawsuit seeks unspecified restitution and civil penalties.
COMMENTS ON THIS ARTICLE: